What is the price of BMRN stock?
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) shares trade continuously during active market hours, reflecting the biotechnology enterprise's commercial performance in delivering specialized treatments for rare genetic diseases and metabolic conditions. Equity valuation is driven by global product adoption rates for its flagship enzyme replacement therapies, robust clinical pipeline advancement milestones, regulatory approvals from health authorities, and quarterly financial earnings reports evaluated closely by healthcare sector analysts.
Related FAQs
BioMarin has not implemented widespread corporate downsizing due to financial distress, but like many large biopharmaceutical enterprises, it occasionally executes targeted workforce adjustments and organizational realignments.
BioMarin Pharmaceutical possesses a promising future driven by its specialized portfolio of innovative therapies targeting rare genetic diseases and orphan conditions.
Wall Street analysts following BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) estimate an average 1-year consensus price target of roughly $87.83 to $90.92. Forecast ranges span from a low target of $50.50 up to a high estimate of $126.00.
BioMarin operates primarily as a biotechnology company, though its comprehensive scope bridges both the biotech and pharmaceutical sectors.
BioMarin Pharmaceutical Inc. is an entirely legitimate, publicly traded, and globally respected biopharmaceutical enterprise.
BioMarin Pharmaceutical Inc. is headquartered in San Rafael, California, United States.
Yes, BioNTech has active and ongoing clinical trials for investigational mRNA-based cancer vaccines.
Determining whether BioMarin Pharmaceutical represents a sound investment involves weighing its strong fundamentals in the rare disease biotechnology market against near-term sector volatility.
BioMarin Pharmaceutical is a global biotechnology company that specializes in developing first-in-class and best-in-class therapeutics for severe rare, genetically defined conditions and lysosomal storage disorders.
Examining the stock volatility of Broadstone Net Lease, Inc.—a real estate investment trust specializing in single-tenant net lease commercial properties—shows a low to moderate volatility profile.
Black Hills Energy employs nearly 3,000 dedicated professionals across its operating footprint. As a prominent electric and natural gas utility subsidiary, the company delivers safe and reliable energy to over 1.
Identifying the best pharmaceutical stocks to purchase depends heavily on prevailing macroeconomic conditions, clinical trial pipeline catalysts, patent expiration timelines, and individual investor risk profiles.
BioMarin Pharmaceutical is considered a strong payer within the biotechnology industry, offering salaries that align with high-demand roles in pharmaceutical research and development.
Wall Street equity research analysts generally evaluate BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) as a favorable "buy" rather than a sell.
Yes, Brookfield Corporation has split its common stock numerous times over several decades of corporate growth.
Evaluating whether BioMarin stock is undervalued depends on an investor's perspective regarding its long-term growth prospects in the rare disease treatment market.
BioMarin Pharmaceutical Inc. (BMRN) carries a consensus Buy rating from healthcare and biotechnology analysts, featuring average 12-month price targets hovering around $88.65 per share.
BioMarin Pharmaceutical specializes in developing and commercializing advanced, breakthrough biotherapeutics for rare genetic and ultra-rare metabolic disorders.
BioMarin Pharmaceutical (BMRN) is set to post its Q2 2026 quarterly earnings after the market closes on Monday, August 3, 2026. Analysts are forecasting earnings of $0.96 per share on revenue of approximately $932 million.
Financial market consensus classifies BioMarin Pharmaceutical primarily as a "buy" to "hold" candidate rather than a sell.